Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Jay Duker

Uveitis and Ocular Inflammatory Disease Boston, MA Medical Doctor

NPI 1508820838 CMS profile 159093

800 Washington St, # 450, Boston, MA 02111

Open in the dashboard

General payments

$22,408

54 records reported · program years 2019–2024

Research payments

$619

Paid to them · 1 record reported · program years 2019–2024

Ownership & investment interest

$135,868

3 holdings reported · through program year 2024

Through program year 2024, Jay Duker of Boston, MA is reported in the CMS Open Payments database as having received $22,408 across 54 general payments and $619 in research payments paid to them. They also declared ownership or investment interests valued at $135,868 across 3 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $127 1
2023 General $167 1
2022 General $154 3
2021 General $64 1
2020 General $8,364 12
2020 Research $619 1
2019 General $13,532 36
2020 Ownership $92,582 2
2019 Ownership $43,286 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jay Duker
  • Uveitis and Ocular Inflammatory Disease median
  • Middle half of Uveitis and Ocular Inflammatory Disease
  • National median

In program year 2025, general payments to Jay Duker were reported at $0. Among 42 Uveitis and Ocular Inflammatory Disease profiles paid that year, the median was $471 and the middle half received between $198 and $5,376.

Show as a table
Year Jay Duker Uveitis and Ocular Inflammatory Disease median Middle half National median
2019 $13,532 $403 $156–$5,734 $163
2020 $8,364 $164 $99–$6,393 $114
2021 $64 $240 $102–$2,572 $132
2022 $154 $503 $154–$5,143 $149
2023 $167 $655 $222–$5,436 $160
2024 $127 $567 $227–$2,571 $164
2025 $0 $471 $198–$5,376 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Novartis Pharmaceuticals Corporation $5,437 6 payments
  2. F. Hoffmann-La Roche AG $4,713 3 payments
  3. Merck Sharp & Dohme Corporation $3,678 9 payments
  4. Bausch & Lomb, a division of Bausch Health US, LLC $3,419 8 payments
  5. EyePoint Pharmaceuticals US, Inc. $2,403 8 payments
  6. Allergan Inc. $1,035 2 payments
  7. Akebia Therapeutics Inc $675 1 payment
  8. Genentech USA, Inc. $361 6 payments
  9. Alcon Vision LLC $317 3 payments
  10. Regeneron Healthcare Solutions, Inc. $192 4 payments
  11. Other $178 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $11,595 6 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,125 1 payment
  3. Food and Beverage $2,457 36 payments
  4. Travel and Lodging $1,731 10 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $1,500 1 payment
Products named General payments · program years 2019–2024
  1. BEOVU $5,274 3 payments
  2. Non-Covered Product $4,713 3 payments
  3. VISUDYNE $3,276 6 payments
  4. MK-8931 $2,650 2 payments
  5. YUTIQ $2,403 8 payments
  6. DEXYCU $803 7 payments
  7. EYLEA $299 5 payments
  8. VABYSMO $281 4 payments
  9. Constellation $167 1 payment
  10. Lucentis $80 2 payments
  11. Other $113 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. F. Hoffmann-La Roche AG $619 1 payment

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$12,171

Medicare's payments for the services billed

Medicare patients

154

Average age 76

Services billed

201

84 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 50%
Diabetes 27%
Chronic kidney disease 25%
Osteoporosis 23%
Ischemic heart disease 21%
Cancer 16%
Depression 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VABYSMO
  • Genentech USA, Inc. $127
$127 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

55 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Uveitis and Ocular Inflammatory Disease in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record